Efficacy and safety of insulin degludec/insulin aspart biosimilar <scp>B01711</scp> vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized

HS-IDegAsp demonstrated comparable efficacy and safety to NN-IDegAsp during the 24-week treatment period in Chinese patients with inadequately controlled T2DM previously treated on once- or twice-daily premixed or basal insulin, with or without OADs.

Authors

Institutions

Publication Details

Journal
Journal of Diabetes Investigation
Published
2025-11-21
DOI
https://doi.org/10.1111/jdi.70175
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized

Chengwei Song, Shuping Zhao, Yunming Gao, Leili Gao et al.
Journal of Diabetes Investigation
Diabetes Management and Research
article

Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized

Chengwei Song, Shuping Zhao, Yunming Gao, Leili Gao, Haiyan Cao, Ziling Li, Xiaojun Cai, Zhifeng Cheng, Jingfang Sun, Wei Li, Xuefeng Li, Xiaoyun Wang, Guoqing Ma, Jianlin Geng, Linong Ji, Yibing Lu
article en

Abstract

HS-IDegAsp demonstrated comparable efficacy and safety to NN-IDegAsp during the 24-week treatment period in Chinese patients with inadequately controlled T2DM previously treated on once- or twice-daily premixed or basal insulin, with or without OADs.

Journal of Diabetes InvestigationVol. 17(1)
Harbin Medical University (CN), Peking University (CN), Yanan University Affiliated Hospital (CN), Heilongjiang Academy of Sciences (CN), Jilin Province Tumor Hospital (CN), Cangzhou Central Hospital (CN), First Affiliated Hospital of Heilongjiang University of Chinese Medicine (CN), People's Hospital of Cangzhou (CN), Baogang Group (China) (CN), Kangmei Pharmaceutical (China) (CN), Taihe Hospital (CN), Fourth Affiliated Hospital of Harbin Medical University (CN), Peking University People's Hospital (CN), First Automotive Works (China) (CN), The First People’s Hospital of Lianyungang (CN), Harrison International Peace Hospital (CN), Second Affiliated Hospital of Nanjing Medical University (CN), Xian Yang Central Hospital (CN), Tonghua Normal University (CN)
Openalex Percentile: Top 52%
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.